Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as brontictuzumab
OMP-52M51 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Brontictuzumab and trifluridine/tipiracil | EXPERIMENTAL | Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label. |
| OMP-52M51 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| brontictuzumab | DRUG | starting dose of 1.5mg/kg administered intravenously (IV) |
| trifluridine/tipiracil | DRUG | - |
| OMP-52M51 | DRUG | - |
Inclusion Criteria: * Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy * ECOG performance status 0 or 1 Exclusion Crit...
OMP-52M51 is an investigational small molecule being developed by Mereo BioPharma Group plc for relapsed or refractory lymphoid malignancies and relapsed or refractory solid tumors. It has been studied in Phase 1 dose escalation trials in adults aged 18 years and older in the United States.
OMP-52M51 has been studied in relapsed or refractory lymphoid malignancies and relapsed or refractory solid tumors. Both are cancer indications in patients whose disease has returned or has not responded to prior treatment. It remains investigational and is not an approved therapy for these or any other conditions.
Mereo BioPharma Group plc is developing OMP-52M51. The company trades on the Nasdaq under the ticker MREO. Mereo BioPharma holds the development program for this small molecule asset across its studied cancer indications.
OMP-52M51 is in Phase 1 development. Its clinical program consists of completed Phase 1 dose escalation studies, and no later-phase trials have been recorded. The drug is investigational and has not been approved by the FDA for any indication.
OMP-52M51 has been evaluated in two completed Phase 1 dose escalation studies. NCT01778439 enrolled 48 participants with relapsed or refractory solid tumors, and NCT01703572 enrolled 24 participants with relapsed or refractory lymphoid malignancies. Both trials were conducted in the United States in adults aged 18 years and older.
The OMP-52M51 clinical program enrolled 48 participants in the solid tumor study NCT01778439 and 24 participants in the lymphoid malignancy study NCT01703572. Both were Phase 1 dose escalation trials, were uncontrolled, and were not randomized or double blinded.